Leadership Team

Airbrush pic.jpg

Michael Dove

Co-Founder & CEO

Michael has experience delivering crucial technology projects supporting clinical trials and regulatory reporting for GSK, Novartis and Merck. His expertise includes project management, customer relationship management, and managing teams. Michael has also supported corporates and start-ups bringing new technologies into healthcare settings to enable clinical decision making.

150219-1.016 LinkedIn.jpg

Ernestas Sirka

Co-founder & CSO

Ernestas has over 6 years of experience in mass spectrometry through his previous positions at Pfizer and University College London (UCL). His expertise includes the development and clinical implementation of targeted protein and lipid biomarker tests, five of which are in routine use today. Ernestas has presented his research outputs at a number of international conferences and co-authored articles in peer reviewed journals, including Nature Medicine.


Advisory Board


Dr. Roman Fischer

Head of Discovery Proteomics at University of Oxford


Professor Adrian Harris

Cancer Research UK Professor of Medical Oncology at University of Oxford


Professor Michael Heneka

Director of Dept. Neurodegenerative Diseases & Gerontopsychiatry at University of Bonn


Jason Foster

Director of Health Equity Consulting
Former General Manager at Indivior
Former Marketing Director for Europe at Reckitt Benckiser


Our Chief Scientific Officer Ernestas Sirka Has 14 Publications Related To Biomarker Development

Massaro, G., Mattar, C.N.Z., Wong, A.M.S., Sirka, E., Buckley, S.M.K., Herbert, B.R., Karlsson, S., Perocheau, D.P., Burke, D., Heales, S., Richard-Londt, A., Brandner, S., Huebecker, M., Priestman, D.A., Platt, F.M., Mills, K., Biswas, A., Cooper, J.D., Chan, J.K.Y., Cheng, S.H., Waddington, S.N., and Rahim, A.A., 2018. Fetal gene therapy for neurodegenerative disease of infants. Nature Medicine. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30013199.

Schofield, D. M., Sirka, E., Keshavarz-Moore, E., Ward, J. M., Nesbeth, D. N., 2017. Improving Fab’ fragment retention in an autonucleolytic Escherichia coli strain by swapping periplasmic nuclease translocation signal from OmpA to DsbA. Biotechnol Lett. 2017 Dec;39(12):1865-1873. doi: 10.1007/s10529-017-2425-z. Epub 2017 Sep 5.

Kinghorn, K., Gronke, S., Castillo-Quan, J.I., Li, L., Woodling, N., Sirka, E., Gegg, M., Hardy, J., and Partridge, L., 2016. A NOVEL MODEL OF GBA1-ASSOCIATED PARKINSON’S DISEASE IMPLICATES AUTOPHAGY [Online]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 87(12).

Kinghorn, KJ; Groenke, S; Castillo-Quan, JI; Woodling, NS; Li, L; Sirka, E; Gegg, M; (2016) A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin. JOURNAL OF NEUROSCIENCE , 36 (46) pp. 11654-11670. 10.1523/JNEUROSCI.4527-15.2016.

Paterson RW, Heywood WE, Heslegrave AJ, Magdalinou NK, Andreasson U, Sirka E, Bliss E, Slattery CF, Toombs J, Svensson J, et al. A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer’s disease pathology. Transl Psychiatry 6(11):e952-e952.

Heywood, WE; Baud, A; Bliss, E; Sirka, E; Schott, JM; Zetterberg, H; et al (2016) A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status. J Vis Exp (116).

Schofield, D., Sirka, E., Ward, J.M., Keshavarz-moore, E., and Nesbeth, D.N., 2016. Optimising cell design steps for efficient removal of E. coli host cell DNA impurities from Fab’ fragment process streams. [Online]. Recovery of Biological Products XVII. Available from: http://www.recoveryconferences.org/welcome.php?top=current-conference

Heywood, WE; Doykov, I; Sirka, E; Clayton, R; Csanyi, B; Cleary, M; et al (2016) Proteomic analysis of urine reveals potential markers for CLN2 Batten disease. In: (Proceedings) 12th Annual WORLD Symposium. (pp. S57-S57). ACADEMIC PRESS INC ELSEVIER SCIENCE (2016).

Rahim, A.A., Sirka, E., Burke, D.G., Buckley, S.M., Cullen, E., Mukherji, S., Herbert, B., Aitchison, K.L., Karlsson, S., Hughes, D.A., Mehta, A.B., Howe, S.J., Heales, S., Mills, K., Cooper, J.D., Cheng, S.H., and Waddington, S.N., 2013. In utero gene therapy rescue of an acute neonatal lethal mouse model of neuropathic Gaucher Disease. In: HUMAN GENE THERAPY. pp.A135–A136.

Heywood, WE; Galimberti, D; Bliss, E; Sirka, E; Paterson, RW; Magdalinou, NK; Carecchio, M; (2015) Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Molecular Neurodegeneration , 10 , Article 64. 10.1186/s13024-015-0059-y.

Mills, K., Sirka, E., Heales, S., Vellodi, A., Cleary, M., Gridnewald, S., Burke, D., Manwaring, V., Bliss, E.J., Bulwer, C., Hindmarsh, P., Warnock, D.G., and Heywood, W.E., 2015. The development of a multiplexed, rapid, mass spectrometry-based test for new and existing biomarkers to identify and monitor kidney disease in pediatric Fabry disease patients. In: MOLECULAR GENETICS AND METABOLISM. Orlando, FL: ACADEMIC PRESS INC ELSEVIER SCIENCE, pp.S81–S81.

Sirka, E., Heywood, W.E., Zhang, X.K., Liu, L., Chuang, W.-L., Doykov, I., Burke, D., Heales, S., Vellodi, A., Cleary, M., Gruenewald, S., Footitt, E., Gissen, P., Hughes, D., and Mills, K., 2015. The development of a rapid, multiplexed UPLC-MS/MS assay for quantitation of lyso-Gb3 and Gb3 in dried blood spots. In: MOLECULAR GENETICS AND METABOLISM. Orolando, FL: ACADEMIC PRESS INC ELSEVIER SCIENCE, pp.S107–S107. 

Bulwer, C., Mills, K., Sirka, E., and Hindmarsh, P., 2014. Urinary vitamin E metabolites as a biomarker of oxidative stress in type 1 diabetes [Online]. Endocrine Abstracts. Available from: http://www.endocrine-abstracts.org/ea/0036/ea0036OC7.2.htm

Rahim, A.A., Burke, D.G., Buckley, S.M., Cullen, E., Mukherji, S., Mills, K., Sirka, E., Herbert, B., Karlsson, S., Hughes, D.A., Mehta, A.B., Howe, S.J., Heales, S., Cooper, J.D., Cheng, S.H., and Waddington, S.N., 2014. Perinatal gene therapy ameliorates a mouse model of neuronopathic Gaucher disease. In: HUMAN GENE THERAPY. pp.A14–A14.